These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment. Ontario Health (Quality) Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487 [TBL] [Abstract][Full Text] [Related]
8. Novel Augmentation Strategies in Major Depression. Martiny K Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173 [TBL] [Abstract][Full Text] [Related]
9. The clinical utility of combinatorial pharmacogenomic testing for patients with depression: a meta-analysis. Brown L; Vranjkovic O; Li J; Yu K; Al Habbab T; Johnson H; Brown K; Jablonski MR; Dechairo B Pharmacogenomics; 2020 Jun; 21(8):559-569. PubMed ID: 32301649 [No Abstract] [Full Text] [Related]
10. Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depression. Rothschild AJ; Parikh SV; Hain D; Law R; Thase ME; Dunlop BW; DeBattista C; Conway CR; Forester BP; Shelton RC; Macaluso M; Brown K; Lewis D; Gutin A; Jablonski MR; Greden JF Psychiatry Res; 2021 Feb; 296():113649. PubMed ID: 33360967 [TBL] [Abstract][Full Text] [Related]
11. Randomized, controlled, participant- and rater-blind trial of pharmacogenomic test-guided treatment versus treatment as usual for major depressive disorder. Perlis RH; Dowd D; Fava M; Lencz T; Krause DS Depress Anxiety; 2020 Sep; 37(9):834-841. PubMed ID: 32383277 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial. Pérez V; Salavert A; Espadaler J; Tuson M; Saiz-Ruiz J; Sáez-Navarro C; Bobes J; Baca-García E; Vieta E; Olivares JM; Rodriguez-Jimenez R; Villagrán JM; Gascón J; Cañete-Crespillo J; Solé M; Saiz PA; Ibáñez Á; de Diego-Adeliño J; ; Menchón JM BMC Psychiatry; 2017 Jul; 17(1):250. PubMed ID: 28705252 [TBL] [Abstract][Full Text] [Related]
13. The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: A meta-analysis. Rosenblat JD; Lee Y; McIntyre RS J Affect Disord; 2018 Dec; 241():484-491. PubMed ID: 30149336 [TBL] [Abstract][Full Text] [Related]
14. A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. Winner JG; Carhart JM; Altar CA; Allen JD; Dechairo BM Discov Med; 2013 Nov; 16(89):219-27. PubMed ID: 24229738 [TBL] [Abstract][Full Text] [Related]
15. Does Pharmacogenomic Testing Improve Clinical Outcomes for Major Depressive Disorder? A Systematic Review of Clinical Trials and Cost-Effectiveness Studies. Rosenblat JD; Lee Y; McIntyre RS J Clin Psychiatry; 2017 Jun; 78(6):720-729. PubMed ID: 28068459 [TBL] [Abstract][Full Text] [Related]